Alteogen Enters into Agreement with Daiichi Sankyo for ENHERTU® Development Using Hybrozyme™ Technology
Monday, November 11, 2024
Alteogen has announced an exclusive licensing agreement with Daiichi Sankyo granting the latter global rights to leverage ALT-B4, Alteogen’s innovative hyaluronidase created with Hybrozyme™ Technology.
ALT-B4 is Alteogen’s proprietary human recombinant hyaluronidase enzyme, developed with the company’s Hybrozyme™ Technology, allowing drugs typically delivered through intravenous (IV) infusion to be administered subcutaneously.
This technology will be used to develop and commercialize a subcutaneous version of ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2-targeting antibody drug conjugate (ADC) jointly developed by Daiichi Sankyo and AstraZeneca.
Under the terms of the agreement, Alteogen will receive an initial payment and may earn additional milestone payments, contingent on the progress of specified development, regulatory, and sales targets met by Daiichi Sankyo.
Alteogen is also set to receive tiered royalties based on product sales following commercialization. Additionally, Alteogen will supply ALT-B4 to Daiichi Sankyo for both clinical and commercial needs.
This is achieved by temporarily hydrolysing hyaluronan in the extracellular matrix, thus enabling the subcutaneous administration of large-volume medications.
Source: prnewswire.com
